Elan & Athena: Selling out, Trading up
Athena's frustration with Wall Street and with its Big Pharma partners clearly led to its willingness to listen to Elan's acquisition offer-other similarly placed biotechs are likely to abandon strategies focused on independence.
You may also be interested in...
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
While the COVID-19 pandemic continued to dominate EU-wide medtech decisions in May, further analysis of the one-year delay to the EU’s new regulations revealed some unexpected consequences. Meanwhile, a new flurry of documents and decisions have been produced by the European Commission.